STOCK TITAN

Actuate Therapeutics Inc - ACTU STOCK NEWS

Welcome to our dedicated page for Actuate Therapeutics news (Ticker: ACTU), a resource for investors and traders seeking the latest updates and insights on Actuate Therapeutics stock.

Actuate Therapeutics Inc (ACTU) delivers targeted therapies through its innovative GSK-3β inhibition platform, focusing on high-impact cancers with limited treatment options. This news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory progress, and strategic initiatives.

Access real-time information about elraglusib's clinical trials across multiple oncology indications, including pancreatic cancer and sarcoma. The page consolidates verified press releases covering trial phases, scientific collaborations, and mechanistic insights into the company's immune-oncology approach.

Key updates include progress reports on combination therapies, FDA communications, and preclinical research validating GSK-3β's role in tumor microenvironments. Content is curated to support informed analysis of the company's pipeline potential while maintaining compliance with financial disclosure standards.

Bookmark this resource for structured updates on Actuate's advancements in overcoming treatment resistance through molecular targeting. Regular visits ensure timely awareness of material developments affecting oncology research and therapeutic innovation.

Rhea-AI Summary

Actuate Therapeutics (NASDAQ: ACTU) has announced that topline data from its Phase 2 study of elraglusib will be presented at the 2025 ASCO Annual Meeting. The presentation will focus on results from the Actuate-1801 Part 3B trial, which evaluated elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).

The oral presentation, scheduled for May 31, 2025, at 3:00 PM CDT, will be part of the Gastrointestinal Cancer session at the conference taking place in Chicago from May 30 to June 3. The study represents a significant milestone in the company's development of therapies targeting GSK-3β inhibition for difficult-to-treat cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.63%
Tags
conferences clinical trial
-
Rhea-AI Summary

Actuate Therapeutics (NASDAQ: ACTU) will present significant data on their cancer drug elraglusib at the AACR Annual Meeting 2025 in Chicago from April 25-30. The presentation focuses on elraglusib's effectiveness in treating advanced salivary gland carcinoma when combined with chemotherapy and immunotherapy.

The first poster presentation (CT212) on April 29 will showcase elraglusib's performance as a GSK-3β inhibitor in advanced salivary cancers. Dr. Glenn Hanna from Dana Farber Cancer Institute reported encouraging response rates in non-Adenoid Cystic Carcinoma patients with nuclear GSK-3β overexpression.

Additionally, researchers from Brown University's Legorreta Cancer Center will present findings on April 28 demonstrating elraglusib's synergistic effects when combined with Jazz Pharmaceuticals' investigational compounds ONC206 and ONC212 for solid cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.79%
Tags
conferences
-
Rhea-AI Summary

Lantern Pharma (NASDAQ: LTRN) reported its Q4 and full-year 2024 results, highlighting significant progress in its AI-driven oncology drug development programs. The HARMONIC™ trial for LP-300 showed an impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with expansion in Japan and Taiwan. LP-184 received two FDA Fast Track Designations for Glioblastoma and Triple Negative Breast Cancer, plus three Rare Pediatric Disease Designations.

The company's RADR® AI platform surpassed 100 billion oncology-specific data points in 2024. Financial results showed cash position of $24.0 million as of December 31, 2024. Q4 net loss was $5.9 million ($0.54 per share), compared to $4.2 million ($0.39 per share) in Q4 2023. Full-year 2024 net loss per share was $1.93 versus $1.47 in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
Rhea-AI Summary

Actuate Therapeutics (NASDAQ: ACTU) announced the completion of patient enrollment in its Phase 2 trial of elraglusib combined with FOLFIRINOX and losartan for untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). The trial, led by Dr. Colin Weekes at Massachusetts General Hospital and supported by the Lustgarten Foundation, enrolled 56 treatment-naïve mPDAC patients. Initial data presented at the AACR Special Conference in September 2024 showed early evidence of enhanced clinical activity. The primary objectives are to assess safety, tolerability, and progression-free survival. Final results are expected in 2026.

CEO Daniel Schmitt highlighted the milestone and noted the potential of elraglusib, citing interim Phase 2 data showing statistically significant improvements in 1-year and median overall survival when combined with gemcitabine/nab-paclitaxel (GnP). The trial involves additional sites, including The University of Colorado and the University of Washington’s Fred Hutchinson Cancer Center. Dr. Weekes expressed optimism about the trial's potential to improve treatment options for mPDAC patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
-
Rhea-AI Summary

Actuate Therapeutics (NASDAQ: ACTU), a clinical-stage biopharmaceutical company specializing in cancer therapies through GSK-3β inhibition, has announced its participation in two major investor conferences in February 2025.

The company's President & CEO, Daniel Schmitt, will attend the BIO CEO & Investor Conference on February 10, 2025, in New York, participating in the 'IPO Class of 2024 Panel' and offering one-on-one meetings with registered attendees.

Additionally, Actuate will be present at the B. Riley Precision Oncology & Radiopharma Conference on February 28, 2025, also in New York, where management will participate in a fireside chat and hold one-on-one meetings arranged through B. Riley representatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
conferences
-
Rhea-AI Summary

Actuate Therapeutics (NASDAQ: ACTU) has received European Medicines Agency (EMA) Orphan Medicinal Product Designation for elraglusib in treating pancreatic ductal adenocarcinoma (PDAC). This designation follows a similar FDA Orphan Drug Designation and recent positive interim Phase 2 trial results.

The interim analysis of the Phase 2 trial showed that elraglusib, combined with gemcitabine/nab-paclitaxel (GnP), demonstrated statistically significant improvements in both 1-year survival rate (p=0.002) and median overall survival (hazard ratio 0.63, p=0.016) compared to GnP alone in metastatic PDAC patients.

The EMA designation, granted for conditions affecting fewer than 2 in 10,000 EU residents, provides benefits including potential 10-year market exclusivity, reduced regulatory fees, and centralized EU approval process. The company expects to report topline Phase 2 data in first half of 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
none
Rhea-AI Summary

Actuate Therapeutics (NASDAQ: ACTU) announced positive interim Phase 2 data for elraglusib combined with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic cancer. The trial met statistical significance on primary endpoints, showing a 43.6% one-year survival rate versus 22.5% in the control group (p=0.002) and a 37% reduction in death risk. Median overall survival increased to 9.3 months compared to 7.2 months in the control arm.

The study demonstrated favorable safety profile with treatment-emergent adverse events similar to the control group. The objective response rate was 27.7% and disease control rate 42.6% in the combination arm versus 20.5% and 33.3% in the control arm. The trial enrolled 286 patients and continues with topline data expected in 1H 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.85%
Tags
-
Rhea-AI Summary

Actuate Therapeutics (NASDAQ: ACTU) announced positive interim Phase 2 data for elraglusib combined with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic cancer. The trial met statistical significance on primary endpoints, showing a 43.6% one-year survival rate versus 22.5% in the control group (p=0.002) and a 37% reduction in death risk. Median overall survival increased to 9.3 months compared to 7.2 months in the control arm.

The study enrolled 286 patients randomized 2:1, demonstrating improved objective response rates (27.7% vs 20.5%) and disease control rates (42.6% vs 33.3%). Multiple patients achieved complete or partial responses with 100% reduction in target lesions. The treatment showed a favorable safety profile, with adverse events similar to the control group. Topline data is expected in 1H 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.85%
Tags
-
Rhea-AI Summary

Actuate Therapeutics (NASDAQ: ACTU), a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat cancers, announced its upcoming addition to the Russell 2000® Index. The inclusion will be effective after U.S. market opens on December 23, 2024, as part of the fourth quarter IPO additions. The Russell 2000® Index, representing approximately 10% of the Russell 3000® Index's total market capitalization, measures the performance of the U.S. equity market's small-cap segment and includes about 2,000 of the smallest securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none
Rhea-AI Summary

Actuate Therapeutics (NASDAQ: ACTU) announced that the FDA has granted rare pediatric disease designation to elraglusib, their GSK-3β inhibitor for treating Ewing sarcoma (EWS). The ongoing Phase 1/2 trial has shown promising results, including two durable Complete Responses in the first six patients with relapsed/refractory EWS. The trial has enrolled 8 patients treated with elraglusib combined with topotecan/cyclophosphamide. Topline Phase 1 data is expected in 2H 2025.

This designation makes Actuate eligible for a Priority Review Voucher upon marketing approval. EWS is the second most common primary malignant tumor in children and adolescents, with 25% of new patients having metastatic disease at diagnosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags

FAQ

What is the current stock price of Actuate Therapeutics (ACTU)?

The current stock price of Actuate Therapeutics (ACTU) is $9.16 as of April 29, 2025.

What is the market cap of Actuate Therapeutics (ACTU)?

The market cap of Actuate Therapeutics (ACTU) is approximately 163.5M.
Actuate Therapeutics Inc

Nasdaq:ACTU

ACTU Rankings

ACTU Stock Data

163.48M
15.75M
18.69%
51.79%
0.4%
Biotechnology
Pharmaceutical Preparations
Link
United States
FORT WORTH